par Asselah, Tarik;Alami, Negar Niki;Moreno, Christophe ;Pol, Stanislas;Karatapanis, Stylianos;Gschwantler, Michael;Horsmans, Y.;Elefsiniotis, Ioannis;Larrey, Dominique;Ferrari, Carlo;Rizzetto, Mario;Orlandini, Alessandra;Calleja, José Luís Uis J.L.;Bruno, Savino;Schnell, Gretja;Qaqish, Roula R.B.;Redman, Rebecca;Pilot-Matias, Tami;Kopecky-Bromberg, Sarah;Yu, Yao;Mobashery, Niloufar
Référence Health Science Reports, 2, 3, e92
Publication Publié, 2019-03
Référence Health Science Reports, 2, 3, e92
Publication Publié, 2019-03
Article révisé par les pairs
Résumé : | Background and Aims: AGATE-I Part I previously reported high sustained virologic response rates in hepatitis C genotype 4 patients with cirrhosis, with 12 and 16 weeks' treatment with a combination of two direct-acting antivirals, ombitasvir and paritaprevir (codosed with ritonavir), plus ribavirin. Part II, reported here, extended the trial to include a 24-week treatment arm to fully assess treatment duration in patients with chronic hepatitis C genotype 4 infection and compensated cirrhosis. Methods: Enrollment took place between June and November of 2015. Treatment-naive and interferon-experienced patients with chronic hepatitis C genotype 4 infection and compensated cirrhosis were enrolled into Arm C; patients previously treated with a sofosbuvir-based regimen were enrolled into Arm D. All patients received a 24-week treatment with ombitasvir, paritaprevir, and ritonavir plus ribavirin. The primary outcome was the proportion of patients with a sustained virologic response (hepatitis C virus RNA < 25 IU/mL) at posttreatment week 12 in the intention-to-treat population. The safety population included all patients who received at least one dose of study drug. Results: In total, 64 patients were enrolled into AGATE-I Part II. Sustained virologic response at posttreatment week 12 was achieved in 57 of 61 patients (93.4%; 97.5% confidence interval, 92.6-97.7) in Arm C and 3 of 3 patients (100%) in Arm D. Two patients were missing SVR12 data, and two prematurely discontinued treatment. The most common adverse events for Arm C were fatigue (16 [26%]) and asthenia (15 [25%]). Results were comparable with those reported in Part I. Conclusions: AGATE-I Part II indicates that extending treatment beyond 12 weeks in genotype 4–infected patients with compensated cirrhosis does not offer additional benefit. |